Vincent Medical Holdings (HKSE:01612) Research & Development: HK$48.7 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01612 Vincent Medical Holdings Ltd HKSE:01612
49 GF Score
Price HK$0.71
GF Value HK$0.58
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Vincent Medical Holdings Research & Development?

Vincent Medical Holdings HKSE:01612 +1.43% 49 Research & Development is HK$48.7 Mil as of Dec. 2025. GuruFocus rates HKSE:01612 with a GF Score™ of 49/100 and a GF Value™ of HK$0.58 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Vincent Medical Holdings's Research & Development for the six months ended in Dec. 2025 was HK$26.8 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$48.7 Mil.

Vincent Medical Holdings  (HKSE:01612) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Vincent Medical Holdings Research & Development Related Terms

Vincent Medical Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Vincent Medical Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vincent Medical Holdings Research & Development Chart

Vincent Medical Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.25 36.68 36.06 30.60 48.74

Vincent Medical Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.92 14.94 15.66 21.90 26.84
HKSE:01612
49GF Score
Vincent Medical Holdings Ltd HKSE:01612
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vincent Medical Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$48.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$48.7 Mil mean?
Vincent Medical Holdings (HKSE:01612) has a Research & Development of HK$48.7 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Vincent Medical Holdings and its competitors.
Is Vincent Medical Holdings' Research & Development too high?
Vincent Medical Holdings' current Research & Development is HK$48.7 Mil. Overall, Vincent Medical Holdings has a GF Score™ of 49/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vincent Medical Holdings' Research & Development compare to ABT and SYK?
Vincent Medical Holdings' Research & Development of HK$48.7 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Vincent Medical Holdings and its competitors. Vincent Medical Holdings's current Research & Development is HK$48.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vincent Medical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Vincent Medical Holdings (HKSE:01612) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$0.58, compared to a current price of HK$0.71 — trading 22.4% above its estimated fair value. The current Research & Development is HK$48.7 Mil. Vincent Medical Holdings' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Vincent Medical Holdings (HKSE:01612), the current Research & Development is HK$48.7 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vincent Medical Holdings (HKSE:01612) Overvalued in 2026?

Based on GuruFocus' analysis, Vincent Medical Holdings stock appears to be overvalued. The current stock price of HK$0.71 is trading 22.4% above its estimated GF Value™ of HK$0.58. GuruFocus considers Vincent Medical Holdings to be Modestly Overvalued.

Key valuation signals for HKSE:01612:

  • Research & Development: HK$48.7 Mil
  • GF Value™: HK$0.58 vs. price of HK$0.71 (22.4% above fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the HKSE:01612 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vincent Medical Holdings Business Description

Address 22 Tak Fung Street, Units 1604-07A, 16th Floor, Two Harbourfront, Hung Hom, Kowloon, Hong Kong, HKG
Vincent Medical Holdings Ltd is an investment holding company engaged in the manufacturing and selling of medical devices focusing on imaging disposable products on an OEM basis to one of the world's diagnostic imaging solutions providers. The company operates in two segments: OEM (original equipment manufacturing) and OBM (original brand manufacturing). The OEM segment manufactures products as per the customer's requirements. The OBM segment includes research, development, manufacturing, marketing, and sales of medical devices under the Inspired Medical, and Hand of Hope brands. The geographical segments of the company includes the United States, Spain, the PRC, Japan, Costa Rica, the Netherlands, Germany, and Others. It derives its maximum revenue from Spain.
49GF Score

Get the complete analysis for HKSE:01612

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.71
Price
HK$0.58
GF Value